[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367639-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367639-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","parp-inhibitor-olaparib-induces-dna-damage-and-acts-as-a-drug-sensitizer-in-an-in-vitro-model-of-canine-hematopoietic-cancer","PARP inhibitor olaparib induces DNA damage and acts as a drug sensitizer in an in vitro model of canine hematopoietic cancer","","Next-generation sequencing-based genetic testing is expanding canine cancer diagnostics, yet in vitro evidence on anti-cancer drugs and their mechanisms in companion animals remains limited. This study evaluated the PARP inhibitor olaparib in canine lymphoma and leukemia cell lines, using olaparib alone and combined with doxorubicin. Cell viability, proliferation, apoptosis induction, and DNA damage were measured, alongside RNA-seq mutational analysis to relate DNA damage response gene differences to drug sensitivity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/parp-inhibitor-olaparib-induces-dna-damage-and-acts-as-a-drug-sensitizer-in-an-in-vitro-model-of-canine-hematopoietic-cancer/367639/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/parp-inhibitor-olaparib-induces-dna-damage-and-acts-as-a-drug-sensitizer-in-an-in-vitro-model-of-canine-hematopoietic-cancer/367639.png","ImageObject",300,407,{"name":42,"@type":43},"Đào","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of the study involving olaparib?","Question",{"text":63,"@type":64},"To demonstrate in vitro activity of olaparib in canine lymphoma and leukemia cells and to clarify its potential use in anti-cancer therapy based on DNA-damage-related gene mutation status.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did olaparib affect the canine cancer cell lines in the experiments?",{"text":68,"@type":64},"Olaparib inhibited metabolic activity, influenced proliferation rates, and caused DNA damage in the tested canine lymphoma and leukemia cell lines.",{"name":70,"@type":61,"acceptedAnswer":71},"How did olaparib act when combined with doxorubicin?",{"text":72,"@type":64},"It functioned as a chemosensitizer by potentiating the cytotoxic effects of doxorubicin.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367639,1790195273,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Pasaol etal. BMC Veterinary Research (2025) 21:439  \n[https://doi.org/10.1186/s12917-025-04880-z](https://doi.org/10.1186/s12917-025-04880-z)  \nBMC Veterinary Research  \nRESEARCH Open Access  \nPARP inhibitor olaparib induces DNA damage and acts as a drug sensitizer in an in vitro model of canine hematopoietic cancer  \nJayson Cagadas Pasaol 1, Ewa Dejnaka 1, Greta Mucignat2, Joanna Bajzert3, Marta Henklewska 1,  \nBożena Obmińska-Mrukowicz 1, Mery Giantin2, Marianna Pauletto2, Christopher Zdyrski4, Mauro Dacasto2 and Aleksandra Pawlak 1,4*  \nAbstract  \nBackground The introduction of genetic tests based on next-generation sequencing techniques into veterinary cancer diagnostics provides information on molecularly targeted therapies useful for dogs. However, there is still a lack of in vitro studies describing the effect and mechanism of action of such anti-cancer drugs in companion animals. Our study aimed to demonstrate in vitro activity of a commonly used PARP inhibitor, olaparib, in canine lymphoma and leukemia cells as well as to indicate its potential uses in anti-cancer therapy based on the mutational status of DNA damage related genes. Canine lymphoma and leukemia cell lines were incubated with olaparib alone and in combination with doxorubicin, and the impact of a single drug and combinations on cell viability, proliferation, induction of apoptosis, and DNA damage were assessed.  \nResults The study showed that olaparib acts as a single agent, inhibiting the metabolic activity of canine lymphoma (CLBL-1, CNK-89) and leukemia (CLB70, GL-1) cells, affecting cell proliferation rates and causing DNA damage. In the tested cells, olaparib also worked as a chemosensitizer, due to its ability to potentiate cytotoxic effects of doxorubicin. Finally, RNA-seq data identify various mutational burden differences in genes involved in the DNA damage response in CLBL-1 and GL-1 cell lines that may explain the observed in vitro sensitivity differences to olaparib.  \nConclusions Olaparib may be an interesting oral therapy alternative to classic chemotherapy or adjuvant option in dogs with hematopoietic cancer with known DNA repair disorders.  \nKeywords Canine lymphoma, Canine leukemia, Targeted therapy, DNA repair, Doxorubicin synergy, Mutational analysis  \n*Correspondence:  \nAleksandra Pawlak  \n[aleksandra.pawlak@upwr.edu.pl](aleksandra.pawlak@upwr.edu.pl)  \n1Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Norwida 31, Wroclaw 50-375, Poland  \n2Department of Comparative Biomedicine and Food Science, Division of Veterinary Pharmacology and Toxicology, University of Padua,  \nLegnaro 35020, Italy  \n3Department of Immunology, Pathophysiology and Veterinary Preventive Medicine, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Norwida 31, Wroclaw 50-375, Poland 4Precision One Health Initiative, College of Veterinary Medicine, University of Georgia, 220 Riverbend Road, Athens, GA 30602, USA  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/.  \nPasaol et al. BMC Veterinary Research (2025) 21:","cbCaionNTxVDSizH","https://ap.wps.com/l/cbCaionNTxVDSizH","pdf",1728596,13,"English","# Abstract\n## Background\n## Results\n## Conclusions\n# Background\n## PARP1 role and mechanism\n## Synthetic lethality concept","[{\"question\":\"What was the main objective of the study involving olaparib?\",\"answer\":\"To demonstrate in vitro activity of olaparib in canine lymphoma and leukemia cells and to clarify its potential use in anti-cancer therapy based on DNA-damage-related gene mutation status.\"},{\"question\":\"How did olaparib affect the canine cancer cell lines in the experiments?\",\"answer\":\"Olaparib inhibited metabolic activity, influenced proliferation rates, and caused DNA damage in the tested canine lymphoma and leukemia cell lines.\"},{\"question\":\"How did olaparib act when combined with doxorubicin?\",\"answer\":\"It functioned as a chemosensitizer by potentiating the cytotoxic effects of doxorubicin.\"}]","PARP inhibitor olaparib induces DNA damage and acts as a drug sensitizer in an in vitro model of canine hematopoietic cancer | PDF",1790171724,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68002f7e09dbf4f1361da8c2f9724e0d.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3dde4331d194990b293e79881f2be460.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/856c38921a00cbdc9be23bb57b97da3b.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1c2b72c6797b44b5c1161e94413bd9a.webp",980,1306]